Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Seoul National University Bundang Hospital | OTHER |
| Kim's Eye Hospital | OTHER |
| Bayer | INDUSTRY |
The purpose of this study is to evaluate the efficacy and safety of aflibercept for treatment of polypoidal choroidal vasculopathy without active polyp.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| polypoidal choroidal vasculopathy without polyp | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| aflibercept | Drug |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change of best-corrected visual acuity (ETDRS letters) | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| presence of subretinal hemorrhage | Total number of months when subretinal hemorrhage are detected on fundus photographs. | during 1 year |
| presence of fluid in macula evidenced by optical coherence tomography |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Seoul National University Bundang Hospital | Seongnam | Gyunggi-do | South Korea | |||
| Konyang University Kim's Eye Hospital |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
Total number of months when fluid in macula are detected on optical coherence tomography
| during 1 year |
| change of indocyanine green angiography | Change of indocyanine green angiography will include followings
| during 1 year |
| Number of eyes which need rescue treatment (photodynamic therapy) | In this study, photodynamic therapy will be performed as a rescue therapy according to the necessary criteria. | during 1 year |
| safety outcomes | frequency and severity of ocular adverse event | one year |
| Seoul |
| South Korea |
| Samsung Medical Center | Seoul | South Korea |
| ID | Term |
|---|---|
| C533178 | aflibercept |
Not provided
Not provided
Not provided